Trial Profile
A Phase 2 Study of Carboplatin, Pemetrexed, and Bevacizumab followed by Bevacizumab and Erlotinib maintenance for Non-squamous Non-Small Cell Lung Cancer not harboring EGFR mutations. (HOT1101)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Jan 2017 Status changed from recruiting to completed.
- 30 Jun 2011 New trial record